Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...

Biosimilars for adalimumab (Humira) had similar efficacy and safety profiles for psoriasis when compared to the original. The meta-analysis appeared recently in the Journal of Dermatological Treatment ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...

Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...